University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing ...

Preliminary studies suggest GLP-1s may offer long-term vision protection for people without diabetes, but researchers caution more research is still needed. During a 10-year study, people without ...

Please provide your email address to receive an email when new articles are posted on . Sura-vec injection reduced the annualized anti-VEGF injection rate by 76% with a high dose and 77% with a low ...

Peter Kaiser, MD, from Ocular Therapeutix, introduces OTX-TKI (Axpaxli), a novel tyrosine kinase inhibitor delivered through a proprietary hydrogel platform. This innovative treatment for wet ...

This is a quickly progressing field, according to Sarju Patel, MD, attending physician at Retinal Consultants of America. He has high expectations that advances from subtly tinted eyeglass lenses to ...

Scientists have developed a new eyedrop that can ferry protective compounds all the way to the retina, paving the way for a less-invasive injection-free method of managing sight-stealing diseases such ...

Screening closing ahead of expectations, with full enrollment now anticipated in 4Q 2025 (previously 1Q 2026) ARTEMIS topline data readout accelerated to 1Q 2027 REDWOOD CITY, Calif., Sept. 22, 2025 ...

– In AVONELLE-X, the largest long-term extension trial in wet AMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end – – Over 60% ...

Advances in neovascular macular degeneration, as presented at the American Society of Retina Specialists (ASRS) 2025 annual meeting, include data on efficacy and dosing intervals for aflibercept 8 mg ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...